Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05187832
Other study ID # AND019-MN-101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 5, 2022
Est. completion date May 2026

Study information

Verified date February 2024
Source Kind Pharmaceuticals LLC
Contact Yusha Zhu, MD PhD
Phone 6467252552
Email yushazhu@kindpharmaceutical.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 [HER2]-negative) breast cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 61
Est. completion date May 2026
Est. primary completion date May 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Key Inclusion Criteria: 1. Postmenopausal women defined as NCCN guideline at the time of informed consent. 2. Histological or cytological confirmation of advanced or metastatic ER+/HER2- breast cancer women who failed standard therapy or for which no standard therapy exists. 3. Prior therapy: 1. No more than 1 line of chemotherapy for advanced breast cancer 2. Recurrence or progression on at least one line of endocrine therapy in the advanced or metastatic disease setting and derived a clinical benefit from the endocrine therapy: Recurred or progressed while being treated with adjuvant endocrine therapy for a duration of at least 24 months, or progressed under endocrine therapy for more than 6 months in the advanced or metastatic setting 4. ECOG score 0-1. 5. Minimum life expectancy of a least 3 months as determined by the Investigator. 6. Evaluable disease per RECIST 1.1; for patients consent to tissue biopsy, disease suitable for tumor biopsy. 7. Sufficient bone marrow reserve and organ function. Key Exclusion Criteria: 1. Previous treatment with any SERDs. 2. Patient any central nervous system metastasis. 3. Prior antitumor therapies: 1. Received chemotherapies within 3 weeks before the first dose. 2. Received systemic radiotherapy within 3 weeks before the first dose, or local radiotherapy within 7 days before the first dose 3. Received other anti-tumor therapy such as endocrine therapy, immunotherapy, and target therapy within 3 weeks or 5 half-lives of the drug before the first dose of the study drug 4. For bone metastasis, bisphosphonates and local remission therapy are allowed (7 days washout for local radiation therapy). 4. Patient who has participated in any other clinical trials for drugs or treatments within 5 half-lives for a prior investigational drug or 2 weeks from use of an investigational device prior to the first dose of study drug. 5. Patient who had major surgery or significant trauma within 4 weeks prior to the first dose of study drug (excluding needle biopsy), or has scheduled surgery during the study period. 6. Patient with serous unhealable wounds/ulcers/fractures within 4 weeks prior to the first dose of study drug. 7. Patient with adverse reactions to previous anti-tumor treatments who have not yet recovered to grade =1 according to CTCAE v5.0. (except for toxicities without safety risks as judged by Investigator, such as alopecia, grade 2 peripheral neuropathy etc.) 8. Patient who has used strong inhibitors or strong inducers of CYP3A, or grapefruit or grapefruit juice within 4 weeks prior to the first dose of study drug. 9. Patient unable to be administered oral medications or any condition that seriously affect digestion in the gastrointestinal tract at the judgement of the Investigator. 10. Patient with active infection within 1 week prior to the first dose of study drug, and currently need systemic anti-infective treatment. 11. Patient has a known history of the following: HIV infection without effective antiretroviral therapy (ART) or acceptable immune function, or syphilis infection, or HBsAg positive HBV or needs prophylaxis therapy or suppressive antiviral therapy before dosing, or has an HCV infection that hasn't completed curative antiviral treatment or with unacceptable viral load. 12. Patient has active cardiac disease or a history cardiac dysfunction. 13. Patient with third spacing that cannot be controlled clinically and is not suitable for the study by the Investigator's judgment. 14. Patient with known history of drug abuse. 15. Patient with mental disorder that, in the opinion of the Investigator, could lead to poor compliance with required study procedures. 16. Patient that cannot tolerate venous blood sampling. 17. Known to have other malignancy within the past 5 years, and is progressing or requires active treatment (except skin basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ who have received potentially radical treatment)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AND019 PO QD
AND019 administrated as oral capsule once per day for 28 days for each cycle

Locations

Country Name City State
United States Sarah Cannon Research Institute Nashville Tennessee

Sponsors (1)

Lead Sponsor Collaborator
Kind Pharmaceuticals LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Progression free survival PFS is defined as the time from treatment start date until objective tumor progression (PD) or death whichever comes first From treatment start date until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Other PD study of AND019 in blood samples Change from baseline in therapy resistant markers by liquid biopsy At predefined timepoints at baseline, Cycle 1 Day 15, Cycle 2 Day 1, and End of Treatment (up to 2 years) (each cycle is 28 days).
Other PD study of AND019 in tissue samples Change from baseline in therapy resistant markers by tissue biopsy At predefined timepoints at baseline and between Cycle 2 Day 1 to Cycle 3 Day 28 (each cycle is 28 days)
Primary Number of participants with adverse events by severity, according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 Number of participants with adverse events From baseline to 12 weeks after the last dose of study treatment (up to 25 months)
Primary PK study of AND019 Plasma concentration of AND019 over time At predefined timepoints at Day 1, Day 8, Day 15, and Day 22 of Cycle 1, and Day 1 of each cycle starting from Cycle 2 (each cycle is 28 days)
Secondary Determine the RP2D To observe the dose limiting toxicity (DLT) and maximum tolerated dose MTD to determine RP2D. From baseline to up to the end of Cycle 1 (each cycle is 28 days)
Secondary Percentage of Participants with Objective Response ORR is defined as a complete response or partial response on two consecutive occasions =4 weeks apart, as determined by the investigator according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1) Baseline and every 8 weeks from Cycle 1 Day 1 until Week 24, and then every 12 weeks until end of study treatment (up to 24 months) (each cycle is 28 days)
Secondary Clinical Benefit Rate CBR is defined as the percentage of participants achieving either of the following: confirmed complete response or partial response (as determined by the investigator according to RECIST v1.1); or the first occurrence of progressive disease after 24 weeks of study treatment. Baseline and every 8 weeks from Cycle 1 Day 1 until Week 24 (each cycle is 28 days)
Secondary Duration of Response DoR is defined as the percentage of participants achieving either of the following: confirmed complete response or partial response. From the first occurrence of a documented objective response until first observation of disease progression or death from any cause on study, whichever occurs first (up to 24 months)
See also
  Status Clinical Trial Phase
Completed NCT00748553 - A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer Phase 1/Phase 2
Completed NCT01625286 - Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients Phase 1/Phase 2
Terminated NCT05932667 - Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer Phase 2
Completed NCT05519059 - Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer Phase 1
Recruiting NCT04742153 - A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC) Phase 2
Not yet recruiting NCT06201234 - Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer Phase 2
Completed NCT02154776 - Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. Phase 1
Active, not recruiting NCT04494425 - Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Phase 3
Active, not recruiting NCT03767335 - MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer Phase 1
Recruiting NCT06105632 - A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment Phase 3
Completed NCT01676753 - Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer Phase 1
Active, not recruiting NCT01226316 - Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules Phase 1